Neurocrine shares took a nasty drubbing after the biotech announced that its low-dose version of an experimental therapy for a rare movement disorder failed a Phase IIb study.
Shares of Canada's Oncolytics surged again this morning after the biotech reported out a final analysis on its tumor virus Reolysin, showing a 92% response rate among a small group of 25 patients enrolled in a Phase II study.
After big gains in its stock price, Biodel shares slipped more than 20% this morning on the back of mid-stage trial results for its fast-acting, mealtime insulin candidate.
CRO giant Covance has signed a deal with the Indiana University School of Medicine, bringing more Phase I studies to the school's on-site clinical research unit and giving Covance a broader footprint for early trials.
Mallinckrodt has rolled out upbeat data from a Phase III study of its experimental pain drug MNK-795 for quelling acute pain in patients after surgeries to remove their bunions. In July the FDA accepted a new drug application for the therapy, an oral extended-release formulation of oxycodone and acetaminophen, for priority review.
GlaxoSmithKline experienced a major R&D setback today, reporting that its targeted cancer immunotherapy MAGE-A3 failed its first co-primary endpoint in a Phase III study for melanoma, failing to beat out a placebo in spurring disease-free survival.
Transgene expected the European commercialization rights to Jennerex's oncolytic virus immunotherapy JX-594 to eventually be worth more than $1 billion. But a Phase IIb trial for the drug has now failed the primary endpoint of overall survival in advanced liver cancer patients.
Rockwell Medical shares surged early today after the biotech announced that its second, duplicate Phase III study for a new iron-delivery drug hit its primary and secondary endpoints, setting the stage for a new drug application.
Cytokinetics shares took a dive in early trading today after its partner Amgen reported that an IV formulation of their heart failure drug omecamtiv mecarbil failed a key Phase II trial, just weeks after Amgen paid $25 million to expand their licensing pact
Teva ($TEVA) today announced that it will dump its depression program for Nuvigil (armodafinil) after the treatment failed its latest Phase III test in a comparison against a placebo.